2Parker SL, Tong T, Bolden S, et al. Cancer statistics,1997. CA Cancer J Clin,1997,47:5-27.
3Greenlee RT, Murray T, Bolden S, et al. Cancer statistics,2000. CA Cancer J Clin,2000,50:7-33.
4Farrow DC, Vaughan TL, Hansten PD. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev,1998,7:97-102.
5Thun MJ, Namboodiri MM, Calle EE, et al. Aspirin use and risk of fatal cancer. Cancer Res,1993,53 :1322-1327.
6Bjorkman DJ. Current status of nonsteroidal anti-inflammatory drug(NSAID) use in the United States:risk factors and frequency of complications. Am J Med,1999,107(6A):3S-8S.
7Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs.A randomized,double-blind,placebo-controlled trial. Ann Intern Med, 1995,123:241-249.
8Wallace JL, Reuter B, Cicala C, et al. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology,1994,107 :173-179.
9Ukawa H, Yamakuni H, Kato S, et al. Effects of cyclooxyenas-2 selective and nitric oxide-releasing nonsteroidal anti-inflammatory drugs on mucosal ulcerogenic and healing responses of the stomach. Dig Dis Sci,1998,43:2003-2011.
10Dimmeler S, Haendeler J, Nehls M, et al. Suppression of apoptosis by nitric oxide via inhibition of interleukin-1β-converting enzyme(ICE)-like and cysteine protease protein(CPP)-32-likeproteases. J Exp Med,1997,185:601-607.
二级参考文献1
1Susan N. Elliott,John L. Wallace. Nitric oxide: A regulator of mucosal defense and injury[J] 1998,Journal of Gastroenterology(6):792～803
